• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[18F]FDG 和 [18F]FLT PET 用于评估三阴性乳腺癌模型中新辅助化疗反应。

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

机构信息

Institute of Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Italy.

Tecnomed, Foundation of the University of Milano-Bicocca, Monza, Italy.

出版信息

PLoS One. 2018 May 23;13(5):e0197754. doi: 10.1371/journal.pone.0197754. eCollection 2018.

DOI:10.1371/journal.pone.0197754
PMID:29791503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5965848/
Abstract

RATIONALE

Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response).

METHODS

Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F]FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm.

RESULTS

We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmax similarly defined tumor response to therapy and that SUVmax variation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline.

CONCLUSIONS

Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel.

摘要

原理

新辅助化疗（NAC）的病理反应是三阴性乳腺癌（TNBC）生存的常用预测指标，因此不断需要识别预测 NAC 反应的标志物。本研究旨在评估 [18F]FDG 和 [18F]FLT PET 成像在区分紫杉醇（PTX）治疗的 TNBC 反应者方面的潜在有用性，与基于肿瘤体积（肿瘤体积反应）的适应性实体瘤反应评估标准（RECIST）标准评估的反应进行比较。

方法

在 PTX 治疗前后，使用 [18F]FDG 和 [18F]FLT PET 评估携带不同大小 TNBC 病变的无胸腺（nu/nu）小鼠。使用基于图的随机游走算法评估 SUVmax、代谢肿瘤体积（MTV）和总病变糖酵解（TLG）和增殖（TLP）。

结果

我们发现，在我们的 TNBC 模型中，[18F]FDG 和 [18F]FLT SUVmax 的变化同样定义了肿瘤对治疗的反应，SUVmax 的变化是最准确的参数。使用肿瘤体积反应（TVR）进行的反应评估表明，PTX 的 NAC 有效性完全独立于基线时的病变大小。

结论

我们的研究在 TNBC 中提供了 PET 的灵敏度和特异性的有趣结果，揭示了 [18F]FDG 和 [18F]FLT 在识别紫杉醇反应者方面的相似性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/c25136ec0082/pone.0197754.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/113dce55660d/pone.0197754.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/a98f05dcaef1/pone.0197754.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/ef9d00146f45/pone.0197754.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/bb0ba12a5a2e/pone.0197754.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/c25136ec0082/pone.0197754.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/113dce55660d/pone.0197754.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/a98f05dcaef1/pone.0197754.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/ef9d00146f45/pone.0197754.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/bb0ba12a5a2e/pone.0197754.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8596/5965848/c25136ec0082/pone.0197754.g005.jpg

相似文献

1
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.[18F]FDG 和 [18F]FLT PET 用于评估三阴性乳腺癌模型中新辅助化疗反应。
PLoS One. 2018 May 23;13(5):e0197754. doi: 10.1371/journal.pone.0197754. eCollection 2018.
2
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.基于 FDG-PET/CT 评估肿瘤代谢和基因组分级指数评估肿瘤增殖预测三阴性乳腺癌新辅助化疗反应。
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4.
3
Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and F-FDG-PET.使用扩散加权 MRI 和 F-FDG-PET 对三阴性乳腺癌顺铂治疗反应的早期预测。
Breast Cancer. 2018 May;25(3):334-342. doi: 10.1007/s12282-018-0834-z. Epub 2018 Jan 22.
4
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.18F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的早期评估有助于预测三阴性乳腺癌新辅助化疗的结果。
Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16.
5
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.在新辅助化疗期间进行 FDG PET/CT 检查可能有助于预测 ER 阳性/HER2 阴性和三阴性乳腺癌的反应，但不能预测 HER2 阳性乳腺癌的反应。
Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.
6
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.18F-FDG PET 检测肿瘤血流变化在新辅助化疗 1 周期后预测三阴性乳腺癌的疗效。
J Nucl Med. 2016 Nov;57(11):1707-1712. doi: 10.2967/jnumed.116.172759. Epub 2016 Apr 21.
7
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.¹⁸F-FDG PET/CT 用于新辅助治疗三阴性乳腺癌早期疗效评估：化疗方案的影响。
J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23.
8
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.[18F]FDG PET/CT 预测新辅助化疗联合或不联合帕博利珠单抗治疗三阴性乳腺癌的结局。
Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22.
9
Complete Metabolic Response on Interim F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.基于中期氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的完全代谢反应预测接受新辅助化疗的乳腺癌患者的长期生存情况
Oncologist. 2017 May;22(5):526-534. doi: 10.1634/theoncologist.2016-0334. Epub 2017 Apr 4.
10
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.3'-脱氧-3'-¹⁸F-氟胸苷PET用于评估乳腺癌对新辅助化疗早期反应的II期研究：来自ACRIN 6688的结果
J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.

引用本文的文献

1
Evaluation of early chemotherapy response by combining static- and dynamic [F]FDG-PET with diffusion-weighted MRI in subcutaneous patient-derived endometrial cancer mouse models.在皮下患者来源的子宫内膜癌小鼠模型中，通过将静态和动态[F]FDG-PET与扩散加权MRI相结合来评估早期化疗反应。
EJNMMI Res. 2025 Apr 18;15(1):45. doi: 10.1186/s13550-025-01235-5.
2
Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.正电子发射断层扫描的创新与乳腺癌治疗反应评估的最新技术水平
J Clin Med. 2023 Dec 27;13(1):154. doi: 10.3390/jcm13010154.
3
Evaluating [F]FDG and [F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models.

本文引用的文献

1
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.基质辅助激光解析电离质谱成像技术评估不同肿瘤模型中紫杉醇的分布异质性。
Sci Rep. 2016 Dec 21;6:39284. doi: 10.1038/srep39284.
2
An enhanced random walk algorithm for delineation of head and neck cancers in PET studies.一种用于PET研究中头颈癌勾画的增强随机游走算法。
Med Biol Eng Comput. 2017 Jun;55(6):897-908. doi: 10.1007/s11517-016-1571-0. Epub 2016 Sep 16.
3
Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
评估 [F]FDG 和 [F]FLT 放射性示踪剂作为三阴性和雌激素受体阳性乳腺癌模型联合治疗反应的生物标志物。
Int J Mol Sci. 2023 Sep 15;24(18):14124. doi: 10.3390/ijms241814124.
4
Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).代谢成像作为一种工具，用于表征三阴性乳腺癌（TNBC）的化疗耐药性并指导治疗。
Mol Cancer Res. 2023 Oct 2;21(10):995-1009. doi: 10.1158/1541-7786.MCR-22-1004.
5
Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.用于指导癌症靶向治疗和研究体内癌症生物学的PET诊断进展。
Curr Pathobiol Rep. 2019 Sep;7(3):97-108. doi: 10.1007/s40139-019-00202-9. Epub 2019 Jul 25.
6
A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative Cu-Labeled Chelator in Mouse Models.一种基于PET放射组学的新型临床前决策支持系统：在小鼠模型中对一种创新的铜标记螯合剂进行评估的初步研究。
J Imaging. 2022 Mar 30;8(4):92. doi: 10.3390/jimaging8040092.
7
Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer.基于适应性氟脱氧葡萄糖正电子发射断层扫描的转移性非小细胞肺癌化疗选择
Cureus. 2021 Oct 15;13(10):e18804. doi: 10.7759/cureus.18804. eCollection 2021 Oct.
8
Economical droplet-based microfluidic production of [F]FET and [F]Florbetaben suitable for human use.基于经济液滴的微流控生产适用于人体使用的 [F]FET 和 [F]Florbetaben。
Sci Rep. 2021 Oct 19;11(1):20636. doi: 10.1038/s41598-021-99111-4.
9
Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging.基于放射性核素成像，Toll样受体5（TLR5）的下调增加了三阴性乳腺癌（TNBC）中的血管内皮生长因子受体（VEGFR）表达。
Front Oncol. 2021 Jul 15;11:708047. doi: 10.3389/fonc.2021.708047. eCollection 2021.
10
Metabolic reprogramming in triple-negative breast cancer.三阴性乳腺癌中的代谢重编程。
Cancer Biol Med. 2020 Feb 15;17(1):44-59. doi: 10.20892/j.issn.2095-3941.2019.0210.
萘二亚胺介导的基因启动子G-四链体稳定对RET癌基因的靶向作用在致癌基因成瘾的人甲状腺髓样癌中发挥抗肿瘤活性。
Oncotarget. 2016 Aug 2;7(31):49649-49663. doi: 10.18632/oncotarget.10105.
4
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.3'-脱氧-3'-¹⁸F-氟胸苷PET用于评估乳腺癌对新辅助化疗早期反应的II期研究：来自ACRIN 6688的结果
J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.
5
18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.新辅助治疗两个周期后的18F-氟脱氧葡萄糖（FDG）PET/CT可预测HER2阴性乳腺癌的反应，但对HER2阳性乳腺癌无效。
Oncotarget. 2015 Oct 6;6(30):29388-95. doi: 10.18632/oncotarget.5001.
6
The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.[(18)F]FDG/[(18)F]FLT PET及扩散加权磁共振成像监测西妥昔尼/多西他赛联合治疗在结直肠癌异种移植模型中的协同效应
Mol Imaging Biol. 2016 Apr;18(2):249-57. doi: 10.1007/s11307-015-0881-1.
7
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.18FDG-PET/CT 相关生物标志物在三阴性乳腺癌新辅助化疗早期疗效预测中的价值
Clin Cancer Res. 2015 Dec 15;21(24):5460-8. doi: 10.1158/1078-0432.CCR-15-0384. Epub 2015 Jun 30.
8
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?基于分子亚型的三阴性乳腺癌个性化治疗的未来会怎样？
Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849.
9
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.¹⁸F-FLT PET/CT作为新辅助化疗治疗局部晚期乳腺癌患者病理反应早期预测的成像工具：一项初步研究。
Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30. doi: 10.1007/s00259-015-2995-8. Epub 2015 Feb 12.
10
Triple-negative breast cancer: new perspectives for targeted therapies.三阴性乳腺癌：靶向治疗的新视角。
Onco Targets Ther. 2015 Jan 16;8:177-93. doi: 10.2147/OTT.S67673. eCollection 2015.